Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing

Bellicum Pharmaceuticals, Inc., a biotechnology company focused on developing safer and more effective cellular immunotherapies, today announced the successful completion of a $55M Series C financing.

http://ift.tt/1wCqYAy